Sale!

RUNX1-RUNX1T1 AML1- ETO t8;21 Qualitative Test

900 د.إ

-25%

The RUNX1-RUNX1T1 AML1-ETO t(8;21) Qualitative Test is a specialized diagnostic assay designed to detect the presence of the RUNX1-RUNX1T1 fusion gene, which results from the translocation between chromosome 8 and 21, denoted as t(8;21). This genetic aberration is commonly associated with certain types of acute myeloid leukemia (AML), making this test a crucial tool for the accurate diagnosis and classification of AML in patients.

Performed at DNA Labs UAE, a leading facility in genetic testing and diagnostics, the test employs sophisticated molecular techniques to identify the specific genetic translocation. This precise identification helps in determining the prognosis of the disease and can significantly influence treatment decisions, including the consideration of targeted therapies that may improve patient outcomes.

The cost of the RUNX1-RUNX1T1 AML1-ETO t(8;21) Qualitative Test at DNA Labs UAE is set at 900 AED. This price reflects the advanced technology and expertise required to accurately perform and interpret the results of this complex genetic test. Patients and healthcare providers considering this test can expect a high level of accuracy and reliability from DNA Labs UAE, alongside comprehensive support throughout the testing process.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

RUNX1-RUNX1T1 AML1-ETO t8;21 Qualitative Test

Cost: 900.0 AED

Symptoms, Diagnosis, and Test Details

The RUNX1-RUNX1T1 gene fusion, also known as AML1-ETO, is a genetic abnormality commonly found in acute myeloid leukemia (AML) patients. It results from a translocation between chromosomes 8 and 21, specifically the t(8;21) translocation. Qualitative testing refers to a diagnostic method that determines the presence or absence of a specific genetic alteration.

In the case of t(8;21), qualitative testing would confirm whether the RUNX1-RUNX1T1 fusion gene is present in a patient’s leukemia cells. This testing can be performed using various molecular techniques, such as polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH). These methods detect the fusion gene’s specific DNA sequence or the physical location of the translocation, respectively.

Qualitative testing for t(8;21) is important for diagnosing AML and determining appropriate treatment options. The presence of this fusion gene is associated with a favorable prognosis, and patients with t(8;21) AML may respond well to certain chemotherapy regimens.

Test Components

  • EDTA Vacutainer (2ml)

Sample Condition

Bone marrow / Peripheral blood (Transport immediately)

Report Delivery

3-4 days

Method

Real Time PCR

Test Type

Genetics

Doctor

General Physician

Test Department

Pre Test Information

RUNX1-RUNX1T1 (AML1-ETO) t(8;21) Qualitative can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Name RUNX1-RUNX1T1 AML1- ETO t8;21 Qualitative Test
Components EDTA Vacutainer (2ml)
Price 900.0 AED
Sample Condition Bone marrow \/ Peripheral blood (Transport immediately)
Report Delivery 3-4 days
Method Real Time PCR
Test type Genetics
Doctor General Physician
Test Department:
Pre Test Information RUNX1-RUNX1T1 (AML1- ETO) t(8;21) Qualitative can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

The RUNX1-RUNX1T1 gene fusion, also known as AML1-ETO, is a genetic abnormality commonly found in acute myeloid leukemia (AML) patients. It results from a translocation between chromosomes 8 and 21, specifically the t(8;21) translocation.

Qualitative testing refers to a diagnostic method that determines the presence or absence of a specific genetic alteration. In the case of t(8;21), qualitative testing would confirm whether the RUNX1-RUNX1T1 fusion gene is present in a patient’s leukemia cells.

This testing can be performed using various molecular techniques, such as polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH). These methods detect the fusion gene’s specific DNA sequence or the physical location of the translocation, respectively.

Qualitative testing for t(8;21) is important for diagnosing AML and determining appropriate treatment options. The presence of this fusion gene is associated with a favorable prognosis, and patients with t(8;21) AML may respond well to certain chemotherapy regimens.